FREE CONSULTATION
INTERNATIONAL PATIENT PROGRAM

SynerTri Immunotherapy:
Advancing Precision Immuno-Oncology

Decades of Immunotherapy Leadership.
Now Personalized to You.

As one of the early medical institutions to clinically implement WT1 dendritic cell vaccine therapy, Precision Clinic Group has developed extensive experience in dendritic cell-based immunotherapy. Today, we continue this clinical and scientific evolution through SynerTri Immunotherapy—our integrated precision strategy for patients with advanced cancer.

What began with dendritic cell vaccine technology has evolved into a broader precision immunotherapy platform tailored to the unique biology of each patient's cancer. Our approach is designed to optimize the conditions under which anti-cancer immunity can function effectively within the tumor microenvironment.

PROVEN EXPERIENCE

6,500+

PATIENTS TREATED

One of the largest clinical experiences in dendritic cell vaccine therapy.

ACADEMIC HERITAGE

Built on technology developed at IMSUT, The University of Tokyo, and further advanced through the WT1 platform pioneered at Osaka University and Hokkaido University.

Global Leadership

World First medical institutions worldwide to clinically implement WT1 dendritic cell vaccine therapy.

A LEGACY OF INNOVATION

The Foundation of WT1 Dendritic Cell Therapy

Our clinical platform is rooted in advanced dendritic cell culture technology developed at The Institute of Medical Science, The University of Tokyo. By integrating the WT1 platform pioneered at Osaka University and Hokkaido University, we helped advance the early clinical application of WT1 dendritic cell vaccine therapy.

Why Experience Matters

Precision Clinic Group represents the continuation of decades of clinical and scientific development in cancer immunotherapy. With more than 6,500 treated cases, our experience supports a treatment platform shaped by long-term clinical practice and patient-centered care.

BEYOND WT1

Toward Individualized Precision Immuno-Oncology

Our platform has evolved beyond shared antigens alone. While WT1 remains an important component, our strategy now incorporates Tumor-Associated Antigens (TAAs), neoantigens, and autologous tumor tissue-derived antigens depending on the biological characteristics of each patient's cancer.

The Shift Toward Neoantigen-Guided Therapy

Using each patient's genomic information, we identify potential neoantigen targets and design personalized neoantigen-based dendritic cell vaccines when appropriate. This allows us to move toward a more individualized precision immunotherapy approach.

WHAT IS SYNERTRI IMMUNOTHERAPY?

An Integrated Precision Strategy

COMPONENT	ROLE	MECHANISM
COMPONENT: 01 — The Accelerator	Dendritic Cell Vaccine Therapy	Supports immune recognition of cancer-specific targets, including WT1, TAAs, neoantigens, and autologous tumor tissue-derived antigens.
COMPONENT: 02 — The Brake Release	Immune Checkpoint Inhibitors	Targets immune suppression pathways such as PD-1, PD-L1, and CTLA-4 that tumors may use to evade immune responses.
COMPONENT: 03 — The Switch	Local Tumor-Directed Therapy	Uses radiation therapy, particle therapy, BNCT, or cryotherapy to help stimulate biological signals associated with anti-tumor immune activation.

SynerTri is not a single drug or procedure. It is an integrated therapeutic platform designed to support effective anti-cancer immune activity within the tumor environment.

BUILT FOR PRECISION

Data-Driven Design

We believe cancer treatment should be guided by the molecular and immunological characteristics of each patient's tumor. By integrating genomic analysis with immunotherapy and local treatment strategies, we aim to develop more individualized approaches to cancer care.

THE TREATMENT JOURNEY

Practical Flow & Planning

Our process is designed for precision at every step.

Consultation & Planning

Tailoring the treatment strategy to your individual tumor profile.

Apheresis

Collecting immune cells from your blood for vaccine manufacturing.

Manufacturing & Storage

Preparing your personalized dendritic cell vaccine.

Administration

Typically administered once every 1–3 weeks.
Initial course: approximately 7 sessions over 4 months.

Neoantigen Note

For neoantigen-based vaccines, genomic analysis and vaccine preparation generally require approximately 2–3 months before administration.

FROM PIONEER RESEARCH TO PRECISION PLATFORM

Precision Clinic Group has participated in the clinical evolution of WT1 dendritic cell vaccine therapy. Today, this experience continues through SynerTri Immunotherapy—an integrated precision platform incorporating neoantigen-guided strategies and personalized immune-based approaches.

Early clinical implementation of WT1 dendritic cell vaccine therapy
Academic foundation involving IMSUT, Osaka University, and Hokkaido University
More than 6,500 treated cases across Tokyo, Nagoya, and Kobe
Continued evolution toward neoantigen-guided precision immunotherapy

FOR INTERNATIONAL PATIENTS

We Welcome Patients from Around the World

Precision Clinic Group offers dedicated support services for international patients, including consultation coordination, treatment planning, and multilingual assistance throughout the treatment process.

▶ REQUEST AN INTERNATIONAL CONSULTATION

SUGGESTED FAQ

Frequently Asked Questions

What is SynerTri Immunotherapy?

An integrated three-component strategy combining dendritic cell vaccine therapy, immune checkpoint inhibitors, and local tumor-directed therapy.

How does it differ from standard vaccine therapy?

It coordinates the vaccine with other treatments to ensure the immune system can strike the tumor effectively.

Is WT1 still used?

Yes. WT1 remains a core component and a key antigen within the SynerTri framework.

Do you offer neoantigen-based vaccines?

Yes. Custom-designed neoantigen approaches are utilized based on detailed genomic analysis.

What is the timeframe for international patients?

Preparation varies; for neoantigen-based vaccines, analysis and manufacturing typically take 2–3 months.

Decades of Immunotherapy Leadership. Now Personalized to You.